Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Natera Inc. (NTRA:NASDAQ), powered by AI.
Natera Inc. is currently trading at $220.11. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Natera Inc. on Alpha Lenz.
View Natera Inc.'s valuation metrics on Alpha Lenz.
“Natera Inc.'s ROE is -14.3%. Explore profitability and growth together.”
Ask for details →Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
“Natera Inc.'s ROE is -14.3%. Explore profitability and growth together.”
Ask for details →Natera Inc. (ticker: NTRA) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 3,282 employees.
The current price is $220.11 with a P/E ratio of -x and P/B of -x.
ROE is -14.32% and operating margin is -13.44%. Annual revenue is $2.3B.